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Abstract
Background: Improving breast cancer survival in sub-Saharan Africa (SSA) is urgently needed, requiring early diagnosis
and improved access to treatment. However, data on the types of and barriers to receiving breast cancer therapy in
this region are limited and have not been compared between different SSA countries and treatment settings.
Methods: In different health care settings across Uganda, Nigeria and Namibian sites of the prospective African Breast
Cancer - Disparities in Outcomes cohort study, we assessed the percentage of newly diagnosed breast cancer patients
who received treatment (systemic, surgery and/or radiotherapy) for cancer and their socio-demographic and clinical
determinants. Treatment data were systematically extracted from medical records, as well as self-reported by women
during 6-month follow-up interviews, and were used to generate a binary indicator of treatment received within
12 months of diagnosis (yes/no), which was analysed via logistic regression.
Results: Of 1325 women, cancer treatment had not been initiated treatment within 1 year of diagnosis for 227
(17%) women and 185 (14%) of women with stage I–III disease. Untreated percentages were highest in two
Nigerian regional hospitals where 38% of 314 women were not treated (32% among stage I–III). At a national
referral hospital in Uganda, 18% of 430 women were not treated (15% among stage I–III). In contrast, at a cancer
care centre in Windhoek, Namibia, where treatment is provided free to the patient, all non-black (100%) and
almost all (98.7%) black women had initiated treatment. Percentages of untreated women were higher in women
from lower socio-economic groups, women who believed in traditional medicine and, in Uganda, in HIV+ women. Self-
reported treatment barriers confirmed treatment costs and treatment refusal as contributors to not receiving treatment.
Conclusions: Financial support to ensure treatment access and education of treatment benefits are needed to improve
treatment access for breast cancer patients across sub-Saharan Africa, especially at regional treatment centres, for lower
socio-economic groups, and for the HIV-positive woman with breast cancer.
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Background
In sub-Saharan Africa (SSA), breast cancer was the most
common cancer diagnosed in women in 2018 [1]. A key
breast cancer control priority in this region is to improve
survival rates which are now among world’s lowest [2].
To do this, as per the Breast Health Global Initiative’s
recommended phased implementation approach, SSA
countries need to develop and strengthen programs to
ensure the early diagnosis of symptomatic breast cancer,
in parallel with improvements in timely access to appro-
priate treatment. Whilst there are several studies on the
predominantly advanced stage at breast cancer diagnosis
in SSA [3], there are limited data on breast cancer treat-
ment gaps from this region.
Standardised breast cancer treatment guidelines tailor
therapy to key tumour features: stage at diagnosis, and
expression of oestrogen, progesterone and HER2 receptors,
for which curative treatment involves some combination of
surgery, radiotherapy and systemic (drug) therapies. Recog-
nising that the majority of countries lack the capacity to
deliver state-of-the-art therapeutics, the National Compre-
hensive Cancer Network (NCCN) has provided resource-
stratified oncology care guidelines, including a SSA-specific
“harmonised” version [4]. Indeed, barriers to accessing on-
cology care are seemingly ubiquitous in parts of SSA. At
the health system level, oncology treatment is lacking and
waiting times for chemotherapy and, if available, radiother-
apy are long [5]. Several further setting-specific factors may
influence treatment acceptability and access. At the patient
level, fear of disfigurement, of stigmatisation or of treat-
ment side-effects have been documented [6, 7], whilst the
risks of incurring catastrophic health expenditures are large
[8, 9]. The influence of traditional and spiritual healers on
receipt of conventional cancer care has not been quantified,
and finally, in HIV-endemic regions of SSA, the evidence
base on management of the HIV-positive woman with
breast cancer is very limited [10].
In 2014, the International Agency for Research on
Cancer (IARC) and the London School of Hygiene and
Tropical Medicine (LSHTM) launched the African Breast
Cancer - Disparities in Outcomes (ABC-DO) study, a
cohort of over 2000 women newly diagnosed with breast
cancer in five SSA countries. This ongoing prospective ob-
servational study collected multidimensional data through-
out the diagnostic, treatment and survivorship period [11].
In analyses to date, advanced stage at diagnosis was associ-
ated with delays to diagnosis, lower socio-economic status
and low levels of breast cancer awareness [12, 13]. Continu-
ing along this breast cancer journey, we herein examine
cancer treatment access and its determinants. The value of
this analysis is to identify SSA-wide and setting-specific op-
portunities for systematic improvements of breast cancer
care which, when coupled with early diagnosis, will trans-
late into averted breast cancer deaths.
Methods
Study design and setting
ABC-DO is a prospective multi-centric hospital-based
study of survival after breast cancer diagnosis in five
SSA countries. A detailed protocol has been published
[11]. During September 2014 to early 2016, all women
aged 18 and older presenting in the participating hospi-
tals and suspected of having breast cancer (either clinic-
ally or through histological confirmation) were invited to
participate. Benign cases were excluded from participa-
tion after diagnostic workup. Across all sites, 99% of
invited women (n = 2265) agreed to participate. In the
present analysis, after excluding 7 women with no treat-
ment data, the partaking hospitals included 1335 women
from (i) Windhoek Central Hospital’s AB May Cancer
Care Centre in Namibia (n = 502, among these n = 398
black women and n = 104 non-black women); (ii)
Uganda Cancer Institute and Mulago Hospital, Kampala
(n = 430) and (iii) the Federal Medical Centre, Owerri,
and Abia State University Teaching Hospital, Aba (n =
313, combined as Nigeria public), and, the only private
setting, the Maranatha clinic, Aba (n = 80), Nigeria. Two
ABC-DO countries that lacked complete or harmonised
treatment information at the time of analysis were not
included, i.e. Zambia (n = 207) owing to a later recruit-
ment period and South Africa (n = 716) due to a differ-
ent data capture system. For the three included
countries, the catchment populations, and breast cancer
treatment options and their approximate costs are listed
in Table 1. The sites include diverse public-sector cancer
care providers, notably two regional hospitals in Nigeria,
a national referral general hospital in Uganda and a spe-
cialised national cancer care centre in Namibia, with
varying out-of-pocket care costs to the patient. Due to
these differences, treatment access is thought to reflect
each site as an example of the cancer treatment setting,
rather than as representative of the country as a whole.
Treatment data
Due to the complexity of multimodality breast cancer
treatment, for the present analysis, we analysed whether
any breast cancer treatment was initiated for each
woman within 12 months of diagnosis (yes/no), which
we defined as having had or commenced at least one of
surgery, radiotherapy or systemic (chemotherapy or
endocrine) therapy. Palliative care without curative in-
tent (e.g. opioids for pain management) was also re-
corded, but was not included here. The binary treatment
indicator was created as follows: First, data was ex-
tracted from two systematically recorded data sources—
medical records and patient self-reporting.
(i) Medical records were collected by medical
personnel of the hospital, separately for surgery
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(n = 523), chemotherapy (n = 712), endocrine
therapy (n = 603) and radiotherapy (n = 324).
Medical records were supposed to be filled in after
each medical consultation for one of the treatments,
to capture the medical decision of both intended
treatments and those actually received (multiple
records per woman are possible): These were used to
capture information on treatment recommendation,
date of administration, completion and specific type
(e.g. specific drug, number of cycles). Research
nurses were prompted by the study’s tailor-made
mHealth application, which was used for all aspects
of data collection, to obtain such data periodically.
(ii) Self-reports: at their 6-month follow-up interview
(n = 1051 women interviewed; 133 (10%) died
beforehand), women were asked whether they
had had each of breast surgery, chemotherapy,
radiotherapy or other treatment and, if not, the
reason therefor.
Secondly, data from these two sources was combined
to create a single indicator of treatment initiated (yes/
no). Thereafter, for women for whom there was no indi-
cation of treatment received from either source, all text
fields of patient follow-up calls, where interviewers could
enter any additional information, were searched for any
indication of treatment status (n = 77 additional treatment
records identified). Thereafter, if there was disagreement in
the information obtained from the medical records and the
self-reported data, the woman was considered to have initi-
ated treatment if the most recent information indicated so:
e.g. if there was no treatment indicated in the medical
records at a certain time of data entry, but self-report data
entered at a later point in time indicated treatment, the pa-
tient was considered treated. If the most recent information
did not report any treatment, the information of the
medical record was considered correct. The 77 women
whose treatment information was obtained via open text
field entries were considered treated.
Table 1 Study hospitals, their catchment populations, available treatments and respective approximate patient out-of-pocket costs
during the study period
Country Namibia Nigeria Uganda
Site Public: AB May Cancer Care
Centre, Windhoek Central
Hospital
Public: Federal Medical Centre Owerri
and Abia State University Teaching
Hospital; Private: Marantha clinic, Aba
Public: Mulago Hospital
and Uganda Cancer
Institute, Kampala
Catchment population National Federal National
ABC-DO participants* 104 non-black and 398
black women
313 public, 80 private patients 430
Medical treatment: approximate patient out-of-pocket costs in USD, at time of study
Imaging
Mammography (diagnostic) Free 22 30
Computer tomography Free 145 100
BiopsyA Free 85 10
Fine-needle aspiration cytology (FNAC)A Free 6 10
Immunohistochemistry (IHC)AB Free Not available 70
Full blood tests Free 40 5
ECG Free 90 20
Mastectomy Free 250 Free
Pre-chemotherapy tests Free No information 50–400
Chemotherapy per cycle Free 65–1500 120–200
Hormone drugs/month
Tamoxifen Free 40 10–20
Anastrazole Free 20 50–60
Herceptin Free 1100 3000
Radiotherapyc Free Nearest public radiotherapy facility
is 150 km away from Enugu
Freec
*Numbers refer to excluded women without any treatment data (n = 7)
ASpecimens were taken for all women in Namibia and 94% and 59% of Ugandan and Nigerian patients, respectively. Most specimens were core biopsies (74%),
followed by excisional biopsies (14%) and Fine Needle Aspiration Cytology (FNAC) (11%). IHC was performed for 96% of Namibian women, but only 10% and 9%
of Ugandan and Nigerian women, respectively
BPrices are for determination of full receptor status (endocrine, progesterone and human epidermal growth factor receptor 2)
cRadiotherapy was not available in Uganda from March 2016 for 1.5 years
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Determinants of treatment received
Socio-economic, breast-specific and other health-related
determinants were examined in relation to treatment re-
ceived. These included the following: (i) five “population
groups” defined according to country (Namibia, Nigeria,
Uganda), ethnicity (black vs. non-black) in Namibia and
hospital type (private vs public) in Nigeria; (ii) recorded
TNM stage at diagnosis: stages I/II combined (as stage I
was rare), stage III, stage IV and unknown stage; (iii) age
at diagnosis (< 40 years, 40–49, 50–59, 60–69 and ≥ 70);
(iv) country-specific socio-economic position (SEP) cat-
egories (low, middle and high) which were constructed
based on thirds of each country’s distribution of a SEP
score derived from combining the following self-re-
ported possessions and facilities: home ownership, in-
door water, flush toilet, electricity, vehicle, refrigerator,
landline, gas or electric stove and a bed; (v) belief in
traditional medicine (yes/no); (vi) employment status as
highly skilled/skilled or unskilled/not applicable (con-
taining, e.g. the informal work sector and housewives);
(vii) body mass index (BMI) derived from measured
height and weight at recruitment (five categories: < 18.5,
18.5 to < 25, 25 to < 30, ≥ 30 kg/m2 and unknown); (viii)
residential area, i.e. living in an urban (city/town) or
rural (village/rural); (ix) previous breast cancer knowledge
(ever/never heard of the disease prior to current disease
onset); (ix) belief in traditional medicine (yes/no); (xi)
belief in spiritual healing (yes/no) and (xii) self-reported
HIV status (yes/no).
At the 6-month follow-up interview, we also ascertained
a woman’s, and her family’s, out-of-pocket healthcare
costs in the past 3 months in the two countries without
free cancer care, i.e. Nigeria and Uganda. Answers were
provided in the local currency and subsequently converted
into US dollars.
Statistical methods
Associations between differences in healthcare systems
and treatment were captured by between-country com-
parisons in treatment received. Within-country determi-
nants of treatment received were identified by fitting
logistic regression models. Minimally adjusted models
were first fitted to all women combined, adjusting for
ABC-DO population group, breast cancer stage and age
at diagnosis. In addition, a fully adjusted model further
included the variables SEP, BMI and residential area.
Population-group heterogeneity was assessed post hoc
via fitting separate stage and age-adjusted models for
Ugandan and Nigerian population groups (models not
fitted for the Namibian population groups due to the
negligible proportion of untreated women in these popu-
lation groups). All analyses were performed in STATA
version 14.2. All P values are two-sided at a significance
level of 0.05. Sensitivity analyses of determinants of
treatment initiation were conducted excluding women
with stage IV breast cancer and results did not change
(results not shown).
Results
Study population
Among the 1335 women included, mean age at breast
cancer diagnosis was 50.7 years (SD = 13.6, Additional file 1:
Table S1). Overall, 597 (45%) of women were diagnosed at
stage III and 204 (15%) at stage IV, with a markedly im-
proved stage distribution in Namibian non-black women.
Most women had unskilled jobs (n = 923; 70%), and other
than in Uganda, where 74% (n = 320) of women lived in
rural areas, the majority resided in urban areas. Nine per-
cent (n = 121) were HIV-positive. A higher percentage of
women reported believing in conventional medicine (94%)
than in spiritual healing (66%) or traditional medicine
(24%).
Percentage of women who had not initiated cancer
treatment
Treatment information was known for 1325 (99%) of
women, of whom 83% (n = 1098) had initiated breast
cancer treatment within 1 year of diagnosis and 17%
(n = 227) had not (Table 2). These percentages varied
greatly between settings, with the highest percentage of
untreated women in the two regional hospitals in
Nigeria, at 38% and 34% in the public and private set-
tings respectively, 17% at the national referral hospital in
Uganda and was near zero in the Namibia Cancer Care
Centre (0% in non-black women and 1.3% in black
women; Fig. 1). Treatment was mostly in the form of
surgery and/or chemotherapy, whilst treatment also
included radiotherapy for two thirds of women at the
Namibian Cancer Care Centre, 15% of women in
Uganda—during a period when the radiotherapy ma-
chine was not in operation for 18 months—and < 5% of
women at the Nigerian regional hospitals.
Odds ratios of associations with receipt of cancer
treatment are provided in Table 2, and those for age,
stage and SEP are plotted in Fig. 2.
Stage
In Nigeria, percentages of untreated women increased
linearly with more advanced cancer stage, with 23% (ab-
solute) more untreated women in stage IV vs stage I/II,
whereas in Uganda only stage IV (and not stage III) had
a higher (by 3%) percentage of untreated women. For
stage III cancer, this association was fully attenuated
after adjusting for SEP, BMI and residential area, thus in
the fully adjusted model, as expected, only stage IV
women had lower treatment odds (stage IV v stage I/II:
0.63, 95% CI 0.37, 1.07, Table 2). In both settings, among
the 8% women with missing stage information, untreated
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Table 2 Breast cancer treatment initiation within 1 year of diagnosis in the ABC-DO cohort: percentage untreated and odds ratios
for initiating treatment associated with socio-demographic, comorbidities and stage at diagnosis
Women not treated
227 (17.2%)
Women treated
1098 (82.8%)
Odds ratios for initiating treatment within 12months
of diagnosis
Test for interaction with
population group
N (row %), all sites combined OR (95% CI)A OR (95% CI)B p
Stage at breast cancer
diagnosis
0.408
I and II 47 (10.4) 403 (89.6) 1 1
III 101 (16.9) 496 (83.1) 0.86 (0.57 to 1.28) 0.96 (0.63 to 1.45)
IV 41 (20.1) 163 (79.9) 0.60 (0.36 to 0.98) 0.63 (0.37 to 1.07)
Unknown 38 (51.4) 36 (48.6) 0.26 (0.14 to 0.45) 0.26 (0.14 to 0.48)
Age at diagnosis 0.640
< 40 64 (20.9) 243 (79.1) 0.70 (0.44 to 1.10) 0.68 (0.42 to 1.10)
40–< 50 65 (17.4) 308 (82.6) 0.83 (0.53 to 1.30) 0.77 (0.48 to 1.23)
50–< 60 46 (14.3) 276 (85.7) 1 1
60–< 70 32 (16.2) 165 (83.8) 0.76 (0.44 to 1.30) 0.74 (0.42 to 1.31)
≥ 70 20 (15.8) 107 (84.2) 0.48 (0.25 to 0.93) 0.57 (0.29 to 1.16)
SEP 0.917
Low 129 (21.5) 408 (78.5) 1 1
Middle 56 (15.1) 382 (84.9) 1.20 (0.81 to 1.79) 1.17 (0.77 to 1.76)
High 42 (11.8) 246 (88.2) 2.40 (1.56 to 3.69) 2.45 (1.53 to 3.90)
Employment 0.941
Unskilled 172 (18.8) 751 (81.2) 0.70 (0.48 to 1.02) 0.83 (0.56 to 1.23)
Skilled 55 (13.8) 348 (86.2) 1 1
BMI (kg/m2) 0.023
< 18.5 9 (11.6) 124 (88.4) 1.58 (0.70 to 3.59) 1.83 (0.79 to 4.21)
18.5–25 103 (20.4) 404 (89.6) 1 1
25–30 67 (17.5) 315 (82.5) 1.09 (0.74 to 1.59) 0.96 (0.65 to 1.41)
30+ 35 (11.5) 269 (88.5) 1.76 (1.10 to 2.81) 1.53 (0.95 to 2.47)
Residential area 0.123
Urban 112 (16.5) 569 (83.5) 1 1
Rural 115 (17.9) 530 (82.1) 0.88 (0.61 to 1.25) 1.07 (0.73 to 1.56)
Breast cancer knowledge 0.286
Yes 170 (15.8) 905 (84.2) 1 1
No 57 (22.7) 194 (77.3) 0.80 (0.54 to 1.17) 0.81 (0.55 to 1.21)
Belief in traditional medicine 0.013
Yes 80 (25.2) 238 (74.8) 0.63 (0.44 to 0.89) 0.67 (0.47 to 0.97)
No 147 (14.6) 860 (83.4)
Belief in spiritual healing 0.004
Yes 149 (17.4) 727 (82.6) 1.18 (0.83 to 1.68) 1.21 (0.84 to 1.21)
No 78 (17.0) 371 (83.0) 1
HIV statusC n.a.
Negative 61 (16.1) 1143 (83.9) 1 1
Positive 16 (32.0) 39 (68.0) 0.39 (0.19 to 0.79) 0.33 (0.16 to 0.70)
BC breast cancer, BMI body mass index, CI confidence interval, OR odds ratio, SEP socio-economic position
AOR adjusted for the ABC-DO population group, breast cancer stage at diagnosis and age at diagnosis
BOR adjusted for the ABC-DO population group, breast cancer stage at diagnosis, age at diagnosis, SEP, BMI and residential area
CLogistic regression models restricted to the Ugandan women (N = 430)
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percentages were particularly high, at 51%, which was not
explained by adjustments made (OR 0.26; 0.14, 0.45).
Age
An inverse U-shaped association between age and
treatment was observed in both settings, with percent-
ages receiving treatment being highest among 50–59-
year-old women. Women aged 70 and over, compris-
ing 6% of patients, were least likely to be treated, with
an absolute difference of 15% in the Nigerian public
setting and 10% in Uganda (OR 0.48, 95% CI 0.25,
0.93) (Additional file 3: Figure S1, Additional file 2:
Table S2). For young women (< 40 years), who repre-
sented 26% of patients, treated percentages were 4%
less in Uganda and 8% less in Nigeria (stage and age-ad-
justed OR 0.70; 95% CI 0.44, 1.10). Further adjustment for
BMI, SEP and area of residence partially attenuated the as-
sociations, but the slight inverse U-shape remained. These
associations held when restricted to HIV-negative women
and were not restricted to women with low SEP or later-
stage disease; instead, they were slightly stronger in early-
stage disease and in medium and high SEP groups (data
not shown).
Socio-economic factors
A consistent and marked socio-economic gradient in the
percentage of untreated women was seen (Fig. 3). Abso-
lute percentages of untreated women in the lowest vs
highest SEP tertiles were 21% vs. 11% in the Uganda
national referral hospital, 41% vs. 21% and 43% vs. 28%
in the two Nigerian regional settings (Additional file 3:
Figure S1, Additional file 2: Table S2). This SEP-treat-
ment association was unaltered after further adjustment
for BMI and residential area (fully adjusted OR 2.45; 95%
CI 1.53, 3.90; Table 2). The association with skilled/un-
skilled employment was in a similar direction, albeit not
statistically significant, whilst there was no clear associ-
ation between residential area and treatment.
Comorbidities
Obese (BMI > 30 kg/m2) and, to a lesser extent and non-
significant, underweight (BMI < 18.5 kg/m2) women each
Fig. 1 Treatment regimens provided within 1 year of breast cancer diagnosis by population group in the ABC-DO cohort study
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had a higher odds of receiving breast cancer treatment
compared to those with a normal BMI (18.5–25 kg/m2)
(age and stage-adjusted OR 1.76; 95% CI 1.10, 2.81 and
1.58; 0.70, 3.59) respectively; Table 1). Further adjust-
ment for SEP and residential area slightly weakened the
obesity association (fully adjusted OR 1.53; 95% CI 0.95,
2.47) but strengthened the underweight association
(1.83; 0.79, 4.21). Regarding HIV, after full adjustment,
HIV-positive women had one third of the odds of being
treated relative to their HIV-negative counterparts
(Table 2), reflecting the Ugandan situation, yet almost all
Namibian black women, the group with the highest
(14%) HIV prevalence (Additional file 1: Table S1), re-
ceived breast cancer treatment. In Uganda, the total per-
centage difference between positive and negative women
was 16%.
Health knowledge and beliefs
Health beliefs affected treatment received, but the effects
were setting-specific (p values for the interaction in
Table 2). In Uganda, where 38% of women reported
believing in traditional medicine, such women were less
likely to receive treatment (27% untreated vs 13% untreated
among non-believers (Additional file 2: Table S2); fully ad-
justed OR 0.39; 95% CI 0.22, 0.66 (population group-spe-
cific ORs not shown)). Further, in the 6-month follow-up
interview, 40% of these women stated that they were cur-
rently attending a traditional healer for treatment. These
were eight times more likely not to have received conven-
tional breast cancer treatment (7.84; 3.64, 16.91). In con-
trast, in the Nigerian private hospital, the odds of being
treated for breast cancer was higher among women who
believed in traditional medicine (fully adjusted OR 5.1; 95%
CI 1.1, 24.7) or in spiritual healing (6.5; 1.2, 34.5) than
among their non-believer counterparts, with the wide CIs
reflecting the small sample size. Finally, previous breast
cancer knowledge was not associated with treatment over-
all, but had an effect in Uganda, where untreated percent-
ages were lower in women who knew that breast cancer
was curable than those who did not (13% v 21%).
(A)
(B)
(C)
Fig. 2 Odds ratios and 95% confidence intervals for receiving treatment by a breast cancer stage, b age at diagnosis and c socio-economic
position, for all women combined and separately for Uganda, and for public and private hospitals in Nigeria. a Adjusted for age at diagnosis,
b adjusted for breast cancer stage and c adjusted for age and stage at diagnosis. Models for all women combined additionally adjusted for
population group
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Self-reported treatment costs and reasons for lack of
treatment
Self-reported information on treatment gaps was avail-
able for 131 women who did not undergo surgery des-
pite medical recommendation; the reasons for refusing
surgery were cost (47%, n = 62) and personal decision
(e.g. due to lack of belief in its effectiveness, fear or non-
compliance to or rejection of therapy) (31%, n = 40). In
addition, for 55 women, a medical reason for not getting
surgery was recorded in the clinical notes (e.g. too old
and frail, tumour too advanced).
Healthcare expenses were paid out-of-pocket by the
patient herself (ranging from 42% in Uganda to 67% in
Nigerian public hospitals) or by family and friends (65%,
all settings). Median household healthcare expenses in a
3-month snapshot period increased with increasing SEP
(Fig. 3B1-B3: range $196 to 270 in Uganda, $56 to 224
in Nigerian public and $102 to 140 in Nigerian Private
hospitals) and tended to be associated with increasing
percentages of treated women, particularly so for Niger-
ian public hospitals (Fig. 3B2). Although only asked for a
3-month interval, it is likely that the cumulative costs
will exceed the annual gross national income per capita
of 600 USD in Uganda and 2100 USD in Nigeria (2017
census; https://data.worldbank.org). Untreated women
also incurred healthcare expenses, with median house-
hold expenses of 83, 20 and 55 USD, respectively, for
women in Uganda, Nigeria public and Nigeria private
hospitals (all SEPs combined).
Discussion
In this prospective African breast cancer cohort, we
found large between-setting differences in cancer treat-
ment access. Whilst almost all women who attended a
specialised Cancer Care Centre in Namibia received
treatment regardless of race and SEP, one in six patients
(A) (B1)
(B2) (B3)
Fig. 3 Household health-related expenses associated with breast cancer treatment. a The percentage of treated women per setting-specific
tertile of household breast cancer expenditure. Tertiles of expenditure relate to the site-specific 3-monthly health-related household expenses and
may be interpreted as low, medium and high levels of expenditure. b1–b3 Household health-related expenses during the last 3 months
corresponding to 50th, 75th and 90th percentile cut-offs for women in low, medium and high socio-economic positions, by an ABC-DO setting.
Local currencies were converted to USD. The gross national income (GNI) per capita in 2017 was 600 USD in Uganda and 2100 USD in Nigeria
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at Uganda’s major referral hospital and one in three
patients at two regional settings in Nigeria had not initi-
ated any type of cancer treatment within 1 year of
diagnosis. In Uganda and Nigeria, countries without uni-
versal health care coverage, financial barriers, ageing, HIV
positivity and traditional medicine health beliefs and a
slight suggestion that young age (< 40) increased treat-
ment gaps. The absence of a clear difference in treatment
rates between stage IV compared to stage I–III patients
among all settings highlights the need for cancer care edu-
cation in the SSA region (percentages of untreated women
per stage displayed in Additional file 2: Table S2).
Plausibility and comparison with other studies
The treatment divide between ABC-DO countries re-
flects, to a large extent, the marked differences in health-
care systems and out-of-pocket costs to women and
their families. In Namibia, where cancer treatment is
free, almost all women attending the cancer care hos-
pital were willing to be treated. In contrast, in Uganda
and Nigeria, cancer care costs are paid out-of-pocket by
the patients, often with the help of relatives and friends.
Accordingly, SEP was the most influential determinant
of treatment access, in line with, but of larger magnitude
than, other studies linking social status to cancer out-
comes [14–17]. Expenditure levels amounted to financial
catastrophe, which have also been reported for other
LMIC, mainly in the Asian region [8, 9].
We found slight inverse U-shaped relationship of treat-
ment with age, which, to the best of our knowledge, has
not been reported so far and warrants investigation in
other settings. Elderly women may not receive treatment
due to their frail physical condition or patients’ preference
[18, 19]. The lower treatment percentage seen in younger
women is of concern and possibly arises in these settings
due to stigma, fear of disfigurement and abandonment.
Preference for traditional medicine also prevented women
from initiating cancer treatment in Uganda. Feelings of
stigmatisation, hopelessness and fatalism are commonly
reported by patients diagnosed with breast cancer in SSA
[20, 21]. Such feelings, together with lack of knowledge of
the disease, contribute to rejection of allopathic cancer
treatments and preference for traditional medical practi-
tioners (TMPs), who are often cancer illiterate and do not
take the adequate action [22].
Increases in life expectancy of HIV-positive women com-
bined with rises in the incidence of breast cancer leads to
an increasing number of women in SSA with the double
HIV-breast cancer burden. In Uganda, HIV-positive women
were less likely to get treatment than their HIV-negative
counterparts, but the reasons for this were unknown. A
personalised treatment management plan is needed to min-
imise possible drug-drug interactions of chemotherapy with
ARVs in the HIV-positive breast cancer patient [23]. Non-
medical reasons for the lower treatment proportions rates
might include stigmatisation as well as poor treatment liter-
acy of the patients and health care workers.
Study strengths and limitations
The study benefits from detailed epidemiologic and
time-indexed treatment data, collected via a mHealth
application which enabled prospective collection of stan-
dardised data across multiple sites, including prompts to
interviewers for data extraction and follow-up inter-
views. The reliability of data on whether treatment was
received was strengthened by the multiple sources—in
particular that of the 1098 (83%) women that have been
considered as treated across the sites, this information
was confirmed by the women for 66% (n = 880), thus re-
ducing the possibility for incorrect overestimation due
to mislaid case notes to 17%. Nevertheless, the latter fac-
tor may have affected the seemingly higher percentage
untreated in women with unknown stage.
A limitation of the present study is the difficulty to
disentangle whether untreated proportions are rather at-
tributable to a country or the specific hospital setting in
this specific country. This is due to the hospital-based
nature of ABC-DO, and hence, the treatment propor-
tions reported reflect those among women who reach
this level of the cancer care system in a given country.
This is particularly relevant for the Namibian specialised
Cancer Care Centre, where the high treated percentages
are among women who have already made the journey
to this national referral centre. Nevertheless, the high
treated proportions in this centre also reflect willingness
of women to receive treatment when the burden of
treatment costs is alleviated from the patient. Further,
the national hospital referral network in Namibia might
heighten the chance of a patient to reach cancer care at
a specialised centre. In every setting, breast cancer pa-
tients who do not reach this level of the health system and
may be more likely to go untreated, are not included. Such
patients may be substantial in number as various patient-
level and health system-level barriers prolong the journey
to breast cancer diagnosis [12], thus overall untreated pro-
portions may be even higher. We do, however, expect that
the profile of women vulnerable to under/no treatment
are captured in the associations observed.
Health system implications
The study identified marked inequities in access to
breast cancer treatment in SSA settings. The much
lower treatment rates in Uganda and Nigeria, when com-
pared to Namibia, underline the importance of providing
population-wide affordable cancer care through universal
healthcare coverage (UHC) and a national hospital referral
network. Even in the absence of UHC, knowledge that
lower social groups are vulnerable to treatment gaps
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should be addressed, and navigational, financial and edu-
cational support provided to reduce these. Appropriate
treatment facilities across the continuum of cancer diag-
nosis and care are currently lacking in most SSA countries
[15, 24, 25]. In a mathematical cost-effectiveness model-
ling of cancer treatment in SSA, BC treatment of all stages
has been shown cost-effective if also accompanied by early
detection programs [26]. In particular at earlier stages,
treatment is more cost-effective, as treatment is less
expensive with higher chances to cure. Costs of BC treat-
ment in Africa were estimated at $78 per disability-ad-
justed life year (DALY) for treating early-stage breast
cancer with surgery and radiotherapy vs. $4986 per DALY
for treating metastatic BC with systemic chemotherapy. In
this context [27], the high percentage of patients who were
not treated within the first year of diagnosis though diag-
nosed at earlier stages, especially stage II, needs to be
urgently addressed.
The present results also highlight the need to consider
how to integrate the informal health care sector into can-
cer care, particularly in countries where traditional med-
ical practitioners (TMPs) serve a large part of the
population. TMPs are a significant source of health care
delivery in cancer management in SSA [22]. On average,
one TMP serves 400 persons, contrasting with one allo-
pathic practitioner per 12,000 persons and two surgeons
per 100,000 persons [28]. In a survey asking TMPs about
cancer management, their literacy was still limited: the
majority of TMPs recognised cancer, but only at advanced
stages [22]. Further, most TMPs believed that they could
treat cancer; thus, appropriate referral for the specialised
diagnosis and care needed for breast cancer would be de-
layed. Thus providing training courses on breast cancer
awareness and recognition, and the importance of imme-
diate hospital referral and treatment initiation and com-
pletion, is a potential promising approach to significantly
improve access to breast cancer diagnosis and treatment
in SSA. Such educational programs need to include the
affected breast cancer patients themselves, but also TMPs
and conventional health care providers at the frontline
and at key referral nodes to both accelerate the route to
diagnosis and increased treatment access.
Conclusion
In conclusion, the present results provide up-to-date em-
pirical data on woman’s access to breast cancer treatment
in SSA, and on the key role played by major financial and
some sociocultural barriers. The marked between-country
divide in treatment access, coupled with the marked and
consistent within-population socio-economic differentials
in the proportion of untreated patients, supports the call
for universal free access to cancer diagnosis and treatment
in SSA to prevent growing social inequities in breast can-
cer care and survival in the region.
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